Evotec Announces the Expansion of Its GMP Sterile Pharmaceutical Manufacturing Facility
Posted on: Tuesday, 17 July 2007, 06:04 CDT
HAMBURG, Germany, OXFORD, England and GLASGOW, Scotland, July 17 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) announced today the expansion of its sterile pharmaceutical manufacturing facility in Glasgow, Scotland. The Company has doubled its capacity for the aseptic (sterile) GMP manufacture of pharmaceuticals to be used in clinical trials with the new facility being operational with immediate effect.
Evotec's formulations business is a niche provider of contract pharmaceutical development services for the development of formulations of pharmaceuticals intended for parenteral administration and the manufacture of formulated drugs for use in Phase I and Phase II clinical trials. Its client base comprises pharmaceutical and biotechnology companies around the world and it has particular expertise in the development of lyophilised (freeze-dried) formulations and the subsequent sterile manufacture of those formulated drugs. In addition, it has dedicated facilities to assist in the development of cytotoxic (cytotstatic) pharmaceuticals.
The expansion of the facilities is in response to the demand from its clients for clinical supplies of liquid and lyophilised drug product. Evotec has demonstrated its expertise in drug formulation development and sterile manufacturing, offering its clients services of the highest quality and technical standards. These additional facilities will allow Evotec to shorten the lead-time to access its manufacturing capabilities and will save its clients time. This will therefore accelerate the progression of Evotec's clients' drugs into the clinical stage of drug development.
Contact: Evotec AG Anne Hennecke SVP, Investor Relations & Corporate Communications Phone: +49-(0)40-56081-286 Fax: +49-(0)40-56081-333 E-Mail: anne.hennecke@evotec.com
Evotec AG
CONTACT: Contact: Evotec AG, Anne Hennecke, SVP, Investor Relations &Corporate Communications, Phone: +49-(0)40-56081-286, Fax:+49-(0)40-56081-333, E-Mail: anne.hennecke@evotec.com
Source: PRNewswire-FirstCall
Related Articles
- Evotec Initiates Phase I Clinical Studies of Anti-Inflammatory Drug
- Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
- U.S. Army Selects Cogon Systems to Develop Advanced Clinical Decision Support Tools for Hand Held Computers
- Morphotek Signs Development and Clinical Supply Agreement With CMC Biopharmaceuticals A/S for Therapeutic Antibody to Treat Melanoma
- Diosynth Biotechnology Announces Agreement With VGX Pharmaceuticals for Process Development and Clinical Production of VGX-100 for the Treatment of Cancer
- GTC Biotherapeutics Enters into Process Development and Clinical Supply Manufacturing Services Agreement With PharmAthene for Protexia(R)
- University General Hospital Systems and Alliance Development Group Sign $1 Billion US Dollar Healthcare Facilities Development Agreement
- Creede Clinic Raising $160,000 for Facility
- Viral Genetics, Inc. Hires Director of Research to Lead Product Development and Basic Research Efforts for Lab Facility at Torrey Pines Institute at Molecular Studies
 |
 |
User Comments (0)
RSS Feeds